Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial (Q44588075)

4 December 2017

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial (English)

1 reference

4 December 2017

0 references

0 references

chronic heart failure

1 reference

1 reference

Christopher B. Granger

series ordinal

4

object named as

Christopher B Granger

1 reference

4 December 2017

3

Karl Swedberg

1 reference

4 December 2017

1

Salim Yusuf

1 reference

4 December 2017

6

John J V McMurray

1 reference

4 December 2017

2

Marc A Pfeffer

1 reference

CHARM Investigators and Committees

4 December 2017

series ordinal

10

object named as

CHARM Investigators and Committees

1 reference

4 December 2017

7

Eric L Michelson

1 reference

4 December 2017

5

Peter Held

1 reference

4 December 2017

Bertil Olofsson

8

1 reference

4 December 2017

Jan Ostergren

series ordinal

9

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

4 December 2017

1 reference

4 December 2017

362

1 reference

4 December 2017

777-781

1 reference

4 December 2017

9386

1 reference

Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Effect of carvedilol on survival in severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) pro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Ramipril and the development of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914285-7

7 January 2021

10.1016/S0140-6736(03)14285-7

Identifiers

DOI

1 reference

4 December 2017

1 reference